$SEEL
Seelos Therapeutics Inc Stock $seel

$seel Overview Financials Valuation SEC Filings Company Website

2016 Q3 Form 10-Q Financial Statement

#000101749116000215 Filed on August 04, 2016

Income Statement

Concept	2016 Q3	2016 Q2	2015 Q2
Revenue	$4.317M	$464.0K	$462.0K
YoY Change	239.12%	0.43%	-91.53%
Cost Of Revenue	$111.0K	$93.00K	$509.0K
YoY Change	-21.83%	-81.73%	578.67%
Gross Profit	$826.0K	$371.0K	-$47.00K
YoY Change	-26.97%	-889.36%	-100.87%
Gross Profit Margin	19.13%	79.96%	-10.17%
Selling, General & Admin	$1.550M	$2.120M	$2.670M
YoY Change	-35.68%	-20.6%	-7.29%
% of Gross Profit	187.65%	571.43%
Research & Development	$170.0K	$2.503M	$3.107M
YoY Change	-96.31%	-19.44%	47.74%
% of Gross Profit	20.58%	674.66%
Depreciation & Amortization	$70.00K	$80.00K	$80.00K
YoY Change	0.0%	0.0%	300.0%
% of Gross Profit	8.47%	21.56%
Operating Expenses	$1.720M	$4.625M	$5.776M
YoY Change	-75.51%	-19.93%	39.72%
Operating Profit	-$1.720M	-$4.625M	-$5.823M
YoY Change	-70.81%	-20.57%	-567.71%
Interest Expense	-$234.0K	-$258.0K	-$170.0K
YoY Change	-12.36%	51.76%	146.38%
% of Operating Profit
Other Income/Expense, Net	$124.0K	$1.372M	$578.0K
YoY Change	-85.55%	137.37%	-1545.0%
Pretax Income	-$1.600M	-$3.250M	-$5.250M
YoY Change	-68.19%	-38.1%	-533.88%
Income Tax	$1.000K	$2.000K	$0.00
% Of Pretax Income
Net Earnings	-$1.291M	-$3.338M	-$5.245M
YoY Change	-74.35%	-36.36%	-379.44%
Net Earnings / Revenue	-29.91%	-719.4%	-1135.28%
Basic Earnings Per Share			-$0.10
Diluted Earnings Per Share	-$5.864M	-$15.90M	-$0.10
COMMON SHARES
Basic Shares Outstanding	66.35M shares	47.10M shares	50.41M shares
Diluted Shares Outstanding			50.41M shares

Balance Sheet

Concept	2016 Q3	2016 Q2	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.610M	$2.720M	$7.430M
YoY Change	-3.44%	-63.39%	-57.35%
Cash & Equivalents	$5.614M	$2.723M	$7.433M
Short-Term Investments
Other Short-Term Assets	$420.0K	$740.0K	$1.310M
YoY Change	-74.39%	-43.51%	32.32%
Inventory	$800.0K	$778.0K	$411.0K
Prepaid Expenses
Receivables	$398.0K	$687.0K	$664.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$7.236M	$4.925M	$9.816M
YoY Change	-11.38%	-49.83%	-47.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.091M	$1.163M	$1.425M
YoY Change	-15.69%	-18.39%	5.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$83.00K	$78.00K	$149.0K
YoY Change	-41.13%	-47.65%	41.9%
Total Long-Term Assets	$1.174M	$1.241M	$1.574M
YoY Change	-18.19%	-21.16%	8.4%
TOTAL ASSETS
Total Short-Term Assets	$7.236M	$4.925M	$9.816M
Total Long-Term Assets	$1.174M	$1.241M	$1.574M
Total Assets	$8.410M	$6.166M	$11.39M
YoY Change	-12.4%	-45.86%	-43.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.430M	$1.600M	$450.0K
YoY Change	240.48%	255.56%	-60.18%
Accrued Expenses	$3.144M	$2.753M	$2.532M
YoY Change	9.59%	8.73%	40.12%
Deferred Revenue
YoY Change
Short-Term Debt	$7.370M	$8.070M	$920.0K
YoY Change	175.0%	777.17%	-22.03%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.61M	$13.27M	$4.974M
YoY Change	83.89%	166.69%	-28.63%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$3.960M
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$80.00K	$131.0K	$246.0K
YoY Change	-57.89%	-46.75%	256.52%
Total Long-Term Liabilities	$80.00K	$131.0K	$246.0K
YoY Change	-57.89%	-46.75%	256.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.61M	$13.27M	$4.974M
Total Long-Term Liabilities	$80.00K	$131.0K	$246.0K
Total Liabilities	$15.95M	$15.61M	$14.64M
YoY Change	-8.93%	6.61%	108.01%
SHAREHOLDERS EQUITY
Retained Earnings	-$316.0M	-$314.7M	-$301.5M
YoY Change	3.09%	4.38%	11.9%
Common Stock	$308.5M	$305.3M	$298.3M
YoY Change	3.3%	2.35%	6.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.537M	-$9.441M	-$3.250M
YoY Change
Total Liabilities & Shareholders Equity	$8.410M	$6.166M	$11.39M
YoY Change	-12.4%	-45.86%	-43.85%

Cashflow Statement

Concept	2016 Q3	2016 Q2	2015 Q2
OPERATING ACTIVITIES
Net Income	-$1.291M	-$3.338M	-$5.245M
YoY Change	-74.35%	-36.36%	-379.44%
Depreciation, Depletion And Amortization	$70.00K	$80.00K	$80.00K
YoY Change	0.0%	0.0%	300.0%
Cash From Operating Activities	-$860.0K	-$3.230M	-$8.610M
YoY Change	-86.95%	-62.49%	85.96%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$10.00K	-$20.00K
YoY Change	-100.0%	-50.0%	-71.43%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$180.0K	$0.00
YoY Change	-100.0%		-100.0%
Cash From Investing Activities	$0.00	$170.0K	-$20.00K
YoY Change	-100.0%	-950.0%	-103.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.750M	-1.110M	-90.00K
YoY Change	-24.85%	1133.33%	-91.35%
NET CHANGE
Cash From Operating Activities	-860.0K	-3.230M	-8.610M
Cash From Investing Activities	0.000	170.0K	-20.00K
Cash From Financing Activities	3.750M	-1.110M	-90.00K
Net Change In Cash	2.890M	-4.170M	-8.720M
YoY Change	-278.4%	-52.18%	71.99%
FREE CASH FLOW
Cash From Operating Activities	-$860.0K	-$3.230M	-$8.610M
Capital Expenditures	$0.00	-$10.00K	-$20.00K
Free Cash Flow	-$860.0K	-$3.220M	-$8.590M
YoY Change	-86.89%	-62.51%	88.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q2	apri	Common Stock Purchase Agreement Maximum Amount Of Shares To Be Sold CommonStockPurchaseAgreementMaximumAmountOfSharesToBeSold	7800000	shares
CY2016Q2	apri	Entity Public Float Primary Public Offerings Of Securities Threshold EntityPublicFloatPrimaryPublicOfferingsOfSecuritiesThreshold	75000000	USD
	apri	Issuance Of Common Stock And Warrants Value IssuanceOfCommonStockAndWarrantsValue	5003000	USD
CY2016Q2	apri	License Fees Expected Future Proceeds LicenseFeesExpectedFutureProceeds	172074000	USD
CY2016Q2	apri	License Fees Expected Future Proceedson Commercial Launch Payments LicenseFeesExpectedFutureProceedsonCommercialLaunchPayments	27608000	USD
CY2016Q2	apri	License Fees Expected Future Proceedson Regulatory Milestones LicenseFeesExpectedFutureProceedsonRegulatoryMilestones	4897000	USD
CY2016Q2	apri	License Fees Expected Future Proceedson Sales Milestones LicenseFeesExpectedFutureProceedsonSalesMilestones	139569000	USD
CY2016Q2	apri	Public Float Primary Public Offerings Of Securities Percent Of Public Float Eligible To Be Raised If Under Threshold PublicFloatPrimaryPublicOfferingsOfSecuritiesPercentOfPublicFloatEligibleToBeRaisedIfUnderThreshold	0.3333
CY2015Q4	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	2228000	USD
CY2016Q2	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	1272000	USD
CY2016Q2	apri	Sales Revenue Goods Net Third Party Components SalesRevenueGoodsNetThirdPartyComponents	10000	USD
	apri	Sales Revenue Goods Net Third Party Components SalesRevenueGoodsNetThirdPartyComponents	300000	USD
	apri	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.1154
	apri	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.1133
CY2016Q2	apri	Shelf Registration Statement Available Amount ShelfRegistrationStatementAvailableAmount	79000000	USD
CY2014Q3	apri	Shelf Registration Statement Available Amount ShelfRegistrationStatementAvailableAmount	100000000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001017491
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	47100000	shares
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	66350887	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2016Q2	dei	Entity Public Float EntityPublicFloat	23600000	USD
	dei	Entity Registrant Name EntityRegistrantName	APRICUS BIOSCIENCES, INC.
	dei	Trading Symbol TradingSymbol	APRI
CY2015Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1580000	USD
CY2016Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1601000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	519000	USD
CY2016Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	687000	USD
	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	94000	USD
	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	194000	USD
CY2015Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1223000	USD
CY2016Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	591000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3343000	USD
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2753000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	466000	USD
CY2016Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	795000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	298881000	USD
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	305215000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1094000	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	325000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	613000	USD
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	739000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1094000	USD
CY2015Q4	us-gaap	Assets Assets	7781000	USD
CY2016Q2	us-gaap	Assets Assets	6166000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	6217000	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	4925000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11400000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7433000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3887000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2723000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3967000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1164000	USD
CY2016Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	14519169	shares
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	us-gaap	Gross Profit GrossProfit	195000	USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50414481	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61900255	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50414481	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61900255	shares
CY2016Q1	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	10000000	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	50000	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	62000	USD
CY2015Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	509000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	742000	USD
CY2016Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	93000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	326000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	28000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
	us-gaap	Decrease In Restricted Cash DecreaseInRestrictedCash	10000	USD
	us-gaap	Decrease In Restricted Cash DecreaseInRestrictedCash	280000	USD
CY2015Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	135000	USD
CY2016Q2	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	46000	USD
CY2015Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	178000	USD
CY2016Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	179000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	65000	USD
CY2016Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	85000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	137000	USD
CY2016Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	250000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	149000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	145000	USD
CY2015Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1841000	USD
CY2016Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2200000	USD
CY2016Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2211000	USD
CY2015Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	5100000	USD
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2015Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-747000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-611000	USD
CY2016Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1637000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4232000	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2669000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5765000	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2294000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4698000	USD
CY2015Q2	us-gaap	Gross Profit GrossProfit	-47000	USD
CY2016Q2	us-gaap	Gross Profit GrossProfit	371000	USD
	us-gaap	Gross Profit GrossProfit	764000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5245000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-11657000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3336000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	500000	USD
CY2015Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-170000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5837000	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-442000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	133000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-14000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	168000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2024000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-760000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-192000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-383000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-69000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	113000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	136000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	73000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	9000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-23000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-109000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-70000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	384000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-325000	USD
CY2015Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	100000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	300000	USD
CY2016Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	300000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-328000	USD
CY2016Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-258000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-537000	USD
	us-gaap	Interest Paid InterestPaid	199000	USD
	us-gaap	Interest Paid InterestPaid	354000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	469000	USD
CY2016Q2	us-gaap	Inventory Net InventoryNet	778000	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	145000	USD
CY2016Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	121000	USD
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	324000	USD
CY2016Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	657000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	17725000	USD
CY2016Q2	us-gaap	Liabilities Liabilities	15607000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4710000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9527000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	471000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7781000	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6166000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15684000	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	13265000	USD
CY2015Q2	us-gaap	Licenses Revenue LicensesRevenue	0	USD
	us-gaap	Licenses Revenue LicensesRevenue	350000	USD
CY2016Q2	us-gaap	Licenses Revenue LicensesRevenue	50000	USD
	us-gaap	Licenses Revenue LicensesRevenue	50000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10949000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8076000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-178000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	262000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14738000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9502000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-5245000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11657000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-3338000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5843000	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	578000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	288000	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1374000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3690000	USD
CY2015Q4	us-gaap	Notes Payable Current NotesPayableCurrent	9401000	USD
CY2016Q2	us-gaap	Notes Payable Current NotesPayableCurrent	8070000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	5776000	USD
	us-gaap	Operating Expenses OperatingExpenses	12140000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	5081000	USD
	us-gaap	Operating Expenses OperatingExpenses	10291000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5823000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11945000	USD
CY2016Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	507000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	274000	USD
CY2016Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	78000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	200000	USD
CY2016Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	131000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-24000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5000	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5000	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	100000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	188000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1062000	USD
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	737000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10869000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9605000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10900000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2200000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	7800000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	83000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1290000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1163000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	3000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	3000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1526000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3107000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6375000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2787000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5593000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	280000	USD
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-308875000	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-314718000	USD
CY2015Q2	us-gaap	Royalty Revenue RoyaltyRevenue	75000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	163000	USD
CY2016Q2	us-gaap	Royalty Revenue RoyaltyRevenue	304000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	671000	USD
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	387000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	424000	USD
CY2016Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	110000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	369000	USD
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	462000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	937000	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	464000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0136
	us-gaap	Sales Revenue Net SalesRevenueNet	1090000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	614000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1094000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0169
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0178
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0139
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	796000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1667000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.06
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.72
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4054000	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4925000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.95
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.68
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.71
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.06
CY2016Q2	us-gaap	Share Price SharePrice	0.5
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	249000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	249000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-9944000	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	-9441000	USD
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	50414000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49031000	shares
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	61817000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	58433000	shares

Files In Submission

Name	View Source	Status
0001017491-16-000215-index-headers.html	Edgar Link	pending
0001017491-16-000215-index.html	Edgar Link	pending
0001017491-16-000215.txt	Edgar Link	pending
0001017491-16-000215-xbrl.zip	Edgar Link	pending
apri-20160630.xml	Edgar Link	completed
apri-20160630.xsd	Edgar Link	pending
apri-20160630_cal.xml	Edgar Link	unprocessable
apri-20160630_def.xml	Edgar Link	unprocessable
apri-20160630_lab.xml	Edgar Link	unprocessable
apri-20160630_pre.xml	Edgar Link	unprocessable
apri6301610q.htm	Edgar Link	pending
apri63016ex311.htm	Edgar Link	pending
apri63016ex312.htm	Edgar Link	pending
apri63016ex321.htm	Edgar Link	pending
apri63016ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SEEL
Seelos Therapeutics Inc Stock $seel

2016 Q3 Form 10-Q Financial Statement

#000101749116000215 Filed on August 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL Seelos Therapeutics Inc Stock $seel

2016 Q3 Form 10-Q Financial Statement

#000101749116000215 Filed on August 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL
Seelos Therapeutics Inc Stock $seel